



King Saud University
Journal of Saudi Chemical Society

www.ksu.edu.sa
www.sciencedirect.com



ORIGINAL ARTICLE

Synthesis, characterization and coordination chemistry of substituted β -amino dicarbonyls

Ihssan Meskini ^a, Maria Daoudi ^a, Abdelali Kerbal ^a, Brahim Bennani ^a,
Javed Sheikh ^{b,*}, Ali Parvez ^c, Loic Toupet ^d, Taibi Ben Hadda ^{e,*}

^a *Laboratoire de Chimie Organique, Faculté des Sciences Dhar Mehraz, Fès, Morocco*

^b *National Environmental Engineering Research Institute, Nehru Marg, Nagpur, India*

^c *Department of Chemistry, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, India*

^d *Institut de Physique, IPR, UMR CNRS 6251, Université de Rennes 1, Rennes, France*

^e *Laboratoire Chimie Matériaux, Université Mohamed Premier, Oujda, Morocco*

Received 26 November 2010; accepted 24 December 2010

Available online 1 January 2011

KEYWORDS

β -Amino dicarbonyls;
Michael reaction;
Crystallography

Abstract An efficient and facile method for the synthesis of novel structurally diverse β -amino dicarbonyl compounds is described by exploring the aza-Michael addition reaction in an aqueous medium as a key step. Thereby, 2-(aryl-disubstituted-amino-1-yl-methyl)-malonic acid diethyl esters were achieved in a good to excellent yields. These products were easily isolated with enough purity just by using simple recrystallization. The crystals of the compounds (**17**) and (**24**) have been obtained and studied by X-ray crystallographic analyses.

© 2011 King Saud University. Production and hosting by Elsevier B.V.

Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/3.0/).

* Corresponding authors. Tel.: +91 1 323 442 2341; fax: +91 1 323 442 (J. Sheikh).

E-mail addresses: sheikhchemie@gmail.com (J. Sheikh), taibi.benhadda@gmail.com (T.B. Hadda).

1319-6103 © 2011 King Saud University. Production and hosting by Elsevier B.V. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/3.0/).

Peer review under responsibility of King Saud University.

doi:10.1016/j.jscs.2010.12.005



Production and hosting by Elsevier

1. Introduction

The HIV-1 Integrase (HI) is a valid target for chemotherapeutic intervention due to its involvement in the viral replication process (Goldgur et al., 1999; Walker et al., 2007; Gopi et al., 2009). The chemical inhibition of HI could be reached via intermolecular coordination between HI/chemical inhibitor/metals (Mg^{2+} and Mn^{2+} , co-factors of the HI), leading to the formation of bimetallic complexes (Lebon et al., 2002; Dayam et al., 2007; Dayam and Neamati, 2004; Sechi et al., 2009; Zenga et al., 2008). In fact, the most successful strategy to inhibit the HI is to explore the structural core of β -diketo acid type, as briefly illustrated in Fig. 1 (Sorrell et al., 1991; Bacchi et al., 2008; Sechi et al., 2006; Orvig and Abrams, 1999). In view of this, it is highly desirable to obtain the improved protocols for the synthesis of β -diketo acid (Amslinger, 2010).




Figure 1 Some of the HIV inhibitors under clinical trials or those (**I** and **Elvitegravir**) were recently approved by US FDA.

For the preparation of such polydentate ligands, the aza-Michael addition seems to be a key-step (Hayashi et al., 1996). Among the large number of unconventional methodologies, this kind of reaction has widely been employed to generate structurally diverse β -amino dicarbonyl compounds (Zhu et al., 2009; Kumar et al., 2008). Most of these unconventional methodologies have used Lewis acids, which although leading to satisfactory yields but it still requires the alternatives (Basu et al., 2004; Wabnitz and Spencer, 2002). Moreover, the use of an aqueous medium (Ranu and Banerjee, 2007; Ranu and Mandal, 2007; Ranu et al., 2005) has been a successful source in achieving expected results in better yield with greener touch eliminating the use of hazardous solvents. Usually, these types of substrates are less reactive or conversely more resistant to undergo the Michael addition which results in low conversion of the desired adducts. From the synthetic point of view, this is a considerable limitation on the Michael reaction process and poses a significant challenge.

To this end, we decided to investigate the feasibility of applying the aza-Michael reactions to the more challenging substituted alkene derivatives. Our idea is to explore the application of this key-step to the synthesis of a set of polydentate O,O,N-ligands (Scheme 1), in order to highlight the versatility of the procedure as well as to generate some insights regarding the 3D crystalline structure of two compounds (**17**) and (**24**).

2. Chemistry

Our synthetic strategy is very clear. In the first step, 2-arylidene-malonic acid ethyl esters (**1**)–(**13**) were prepared by the condensation of substituted arylaldehydes with diethyl-malonate in ethanol under reflux condition, using piperazine and glacial acetic acid as a catalyst. This procedure furnished the intermediates, 2-arylidene-malonic acid ethyl esters (**1**)–(**13**), quickly and in excellent yields (Scheme 1).

To further explore the scope and limitations of the aza-Michael reaction, compound (**1**) was chosen as the model precursor because of its thermo stability and also due to the less reactivity of pyrazole towards traditional aza-Michael addition. It was found that the stirring of compound (**1**) and pyrazole together in water at room temperature for 12 h led to the formation of 71% of (**15**) (Scheme 2). During the investigation of experimental conditions, it was possible to observe that the acid catalyst (AcOH, 0.1 mol%) accelerates the reaction but it is not essential (Meskini et al., 2010a,b,c).

Having well established and developed reaction conditions, it was identified that precursors (**1**)–(**13**) reacted quickly; with various secondary amines under catalyst-free conditions to provide the desired adducts (**14**)–(**35**) in good to excellent yields. These products were characterized using spectroscopic (^1H and ^{13}C NMR, IR and MS) and micro-analytical data.


The compounds (**14**)–(**35**) are insoluble in water. The compound (**16**) has been recrystallized from ethanol to obtain the single suitable crystal and studied by X-ray diffraction study (Meskini et al., 2010a,b,c). Since, NaOH is a strong base therefore it is likely that the compounds are saponified into carboxylate units upon dissolution to form substituted β -amino dicarboxylates of sodium. However, we were unable to obtain the hypothetical bimetallic species by conventional means. The attempts to crystallise the substituted β -amino dicarboxylate derivative of (**16**) resulted in crystallisation of a polymeric complex; the poly[[bis{13-2-[(3,5-dimethyl-1H-pyrazol-1-yl)(phenyl)methyl]propanedioato}tetrasodium](I) 7.5-hydrate] (**16'**) (Scheme 3). The compound (**16'**) has been used then in our laboratory as a starting material in organometallic chemistry and surprisingly its coordination mode has not been reported previously in literature. Since it is such an important precursor its structure will be briefly described here (Fig. 2).

The coordination of $\text{Cu}(\text{NO}_3)_2 \cdot 2\text{H}_2\text{O}$ to β -amino dicarboxylate ligands (**14**)–(**35**) in basic medium led us to obtain bimetallic complexes (Scheme 4 and Fig. 3).

3. Results and discussion

In order to get more insight into the theoretically possible points of metallic coordination, we have aimed to replace the phenyl by 4-chloro-phenyl, 4-methyl-phenyl or trifluoromethyl-phenyl fragments (Scheme 2).

Analyzing the X-ray crystallography data (Figs. 4 and 5), it has revealed that the crystal is subject of a weak torsion around the C1–C2 bond, of dihedral angle [N(1), C(1), C(2), H(2)] equal to $68.04(2)^\circ$. The nitrogen atom N(1) is trivalent with N(1)–C(1), N(1)–C(15) and N(1)–C(22) bonds of 1.484(1), 1.473(2) and 1.471(2) Å, respectively; they do not remain trans, indicating a *cis* 1,2-addition. Confirmation of the *cis*-addition is also indicated by the ORTEP of compound (**24**) in which it is easy to see the dihedral angle [N(1), C(1), C(2), H(2)] in the same range. This observed geometric form was confirmed by studying the crystallographic features for the compounds (**17**) and (**24**).



Scheme 1 Synthetic protocol for the generation of aminodicarbonyl precursors (1)–(13).

The solid state structures for (17) and (24) (Figs. 4 and 5) were in full agreement with the proposed one than in solution (see Table 1).

4. Experimental protocols

4.1. Materials and methods


Infrared spectra were recorded on a PYE Unicam SP3-300 spectrometer as KBr pellets. The ^1H and ^{13}C NMR spectra were recorded on Bruker spectrometer (250 and 400 MHz) using TMS as internal standard. Chemical shifts are reported downfield from the standard in ppm. The FAB mass spectra were obtained on a NERMANG R10-LOC instrument. For the chemical ionisation ($\text{DCI}/\text{NH}_3/\text{CH}_3$), the compounds were dissolved in DMSO or MeOH and dispersed in a matrix solution, currently the 3-nitrobenzyl (MNBA) or glycerol (GLY). Elemental analyses were performed (Morocco). All common laboratory chemicals were purchased from commercial sources and used without further purification.

4.2. General procedure for the synthesis of intermediates (1)–(13)


To a solution of ethyl malonate (15 g, 93 mmol) in 40 mL of ethanol, were added the respective aldehyde (100 mmol), followed by the addition of 1.5 mL of piperidine and 1 mL of glacial acetic acid. The reaction mixture was then stirred at reflux temperature of ethanol for 12 h, until thin-layer chromatography indicated the complete consumption of the starting material. After removing the solvent under vacuum, the crude product was washed with a saturated solution of sodium bisulfite (20 mL). The product was extracted by diethyl ether (2×20 mL), dried with sodium sulphate and evaporated to give the respective pure yellow oils for (1–3, 6, 7) and microcrystals or white powder for (4, 5, 8–13).

4.2.1. 2-Benzylidene-malonic acid diethyl ester (1)

Yield: 71%; $R_f = 0.7$ (ether/hexane: 1/1); IR (KBr, ν cm^{-1}): 2875–2982 (CH), 1722 (C=O), 1629–1497 (C=C), 1294–1254 (C–O); ^1H NMR (300 MHz, CDCl_3) δ ppm: 7.72 (s,



Scheme 2 Synthetic protocol for the generation of aminodicarbonyl compounds (14)–(35).



Scheme 3 Polymerization of (16) to produce poly[[bis{13-2-[(3,5-dimethyl-1H-pyrazol-1-yl)(phenyl)methyl]propanedioato}tetrasodium(I) 7.5-hydrate] (16').





Figure 2 ORTEPs drawing of compounds (16') (Meskini et al., 2010a,b,c).



Scheme 4 Synthetic protocol for the generation of bimetallic compound (36).




Figure 3 Ortep of the complex $\text{Cu}_2(\text{CH}_3\text{COO}^-)_4(\text{H}_2\text{O})_2$ (36).




Figure 4 ORTEP drawing of compound (17).




Figure 5 ORTEP drawing of compound (24).

Table 1 Crystallographic data for compounds (17) and (24).

	Compound 17	Compound 24
Formula	C ₂₈ H ₃₁ N ₁ O ₄	C ₂₃ H ₂₈ Cl ₁ N ₁ O ₄
<i>M</i>	445.54	417.91
<i>Crystal system</i>		
Space group	<i>P</i> -1	<i>P</i> -1
<i>a</i> (Å)	7.9880 (3)	8.4744 (3)
<i>b</i> (Å)	10.9559 (4)	11.1119 (4)
<i>c</i> (Å)	14.8493 (7)	13.2992 (4)
α (°)	77.269 (4)	70.866 (3)
β (°)	85.682 (4)	77.862 (3)
γ (°)	68.709 (4)	71.331 (3)
<i>Z</i>	2	2
λ (Mo-K α) (Å)	0.71069	0.71073
μ (mm ⁻¹)	0.083	0.199
<i>T</i> (K)	110	110
<i>h</i> , <i>k</i> , <i>l</i> _{max}	10, 13, 18	10, 14, 16
θ _{max}	27.000	27.000
<i>R</i> ₁ [<i>I</i> > 2 <i>p</i> (<i>I</i>)], all data	0.0376 (3467)	0.0314 (3751)
<i>wR</i> ₂ [<i>I</i> > 2 <i>p</i> (<i>I</i>)], all data	0.0900 (5108)	0.0889 (4836)
CCDC number	734201	734199

1H, C=CH-Ph), 7.45–7.32 (m, 5H, Ph), 4.32 (q, 2H, 2OCH₂-CH₃, ³*J* = 7.2 Hz), 4.28 (q, 2H, 2OCH₂-CH₃, ³*J* = 7.2 Hz), 1.31 (t, 3H, 2OCH₂CH₃, ³*J* = 7.1 Hz), 1.25 (t, 3H, 2OCH₂CH₃, ³*J* = 7.1 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.6–166.2 (2C=O), 142.0 (PhCH), 132.8 (C_{quat}, Ph), 130.5 (2C_{tert,meta}), 129.4 (C_{tert,para}), 128.7 (2C_{tert,ortho}), 126.1 (C_{quat}, =C), 61.6–61.6 (2C, 2OCH₂CH₃), 14.1–13.8 (2C, 2OCH₂CH₃); SM (IE): Calc. for C₁₄H₁₆O₄: 248; [M+H]⁺ (*m/z*) = 249 (100%).

4.2.2. 2-(4-Chlorobenzylidene)-malonic acid diethyl ester (2)
Yield: 77%; *R*_f = 0.73 (ether/hexane: 1/1); IR (KBr, ν cm⁻¹): 2906–2982 (CH), 1724 (C=O), 1591–1631 (C=C), 1254–1308 (C–O); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.7 (s, 1H,

C=CH-Ph), 7.45–7.30 (m, 4H, Ph), 4.31–4.4 (2q, 4H, 2OCH₂CH₃, ³*J* = 7.12 Hz), 1.31–1.25 (2t, 6H, 2OCH₂CH₃, ³*J* = 7.11 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.3–163.8 (2C=O), 140.0 (C(Ph)-CH=C), 132.9 (C_{quat}, C–Cl-Ph), 130.3 (2C_{meta}), 130.4 (C_{quat}, para/Cl), 129.0 (2C_{ortho}), 125.4 (C=C-(CO₂Et)₂), 61.4 and 61.7 (2OCH₂CH₃), 13.7 and 13.8 (2OCH₂CH₃); SM (IE): Calc. for C₁₄H₁₅ClO₄: 282.07; [M+H]⁺ (*m/z*) = 283 (100%).

4.2.3. 2-(4-Methoxybenzylidene)-malonic acid diethyl ester (3)
Yield: 66%; *R*_f = 0.71 (ether/hexane: 1/1); IR (KBr, ν cm⁻¹): 2840–2982 (CH), 1725 (C=O), 1512–1574 (C=C), 1253–1305 (C–O), 1170, 1118, 892.416; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.7 (s, 1H, C=CH-Ph), 6.90–7.40 (m, 4H, arom), 4.20–4.30 (2q, 4H, 2OCH₂-CH₃, ³*J* = 7.15 Hz), 1.30–1.40 (2t, 6H, 2OCH₂CH₃, ³*J* = 7.14 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 165–161.57 (2C=O), 141.79 (-CH=), 182 (-C_{quat}, C-OCH₃-Ph), 131.59 (2C_{meta}, arom), 127 (C_{quat}, para/OCH₃), 130.87 (2C_{ortho}, arom), 125.41 (=C-(CO₂Et)₂), 61.63–61.45 (2CH₂-CH₃), 13.97–14.06 (2OCH₃CH₂), 3.23 (s, 3H, OCH₃-Ph).

4.2.4. 2-(4-Dimethylaminobenzylidene)-malonic acid diethyl ester (4)
Yield: 83%; *R*_f = 0.24 (ether/hexane: 1/1); mp: 120 °C; IR (KBr, ν cm⁻¹): 2905–2987 (CH), 1721 (C=O), 1582–1527 (C=C), 1298–1318 (C–O), 1226, 1113, 727, 419; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.62 (s, 1H, C=CH-Ph), 6.61 (d, 2H, arom), 7.34 (d, 2H, arom), 4.20–4.30 (2q, 4H, 2OCH₂CH₃, ³*J* = 7.18 Hz), 1.29–1.30 (2t, 6H, 2OCH₂CH₃, ³*J* = 7.17 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 165.05–167.93 (2C=O), 142.63 (-CH=C), 151 (C_{quat}, C-N(CH₃)₂-Ph), 111.54 (2C_{meta}, arom), 120.15 (C_{quat}, para/N(CH₃)₂), 131.88 (2C_{ortho}, arom), 119.97 (C=C-(CO₂Et)₂), 61.35–61.03 (2OCH₂CH₃), 14.27–14.54 (2OCH₃CH₂).

4.2.5. 2-(4-Nitrobenzylidene)-malonic acid diethyl ester (5)
Yield: 45%; *R*_f = 0.22 (ether/hexane: 1/1); mp: 168 °C; IR (KBr, ν cm⁻¹): 2852–2988 (CH), 1713 (C=O), 1492–1518 (C=C), 1250–1299 (C–O), 1199, 1063, 748, 412; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.7 (s, 1H, C=CH-Ph), 8.3 (d, 2H, arom), 7.8 (d, 2H, arom), 4.3–4.40 (2q, 4H, 2OCH₂CH₃), 1.2–1.30 (2t, 6H, 2OCH₂CH₃); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.26–165.2 (2C=O), 138.78 (Ph-CH=C), 205 (-C_{quat}, C-NO₂-Ph), 123 (2C_{meta}, arom), 120.15 (C_{quat}, para/N(CH₃)₂), 130.26 (2C_{ortho}, arom), 130 (=C-(CO₂Et)₂), 61.62 (C, 2OCH₂CH₃), 13.25–14.45 (C, 2OCH₃CH₂).

4.2.6. 2-(4-Methylbenzylidene)-malonic acid diethyl ester (6)
Yield: 76%; *R*_f = 0.67 (ether/hexane: 1/1); IR (KBr, ν cm⁻¹): 2906–2982 (CH), 1723 (C=O), 1590–1632 (C=C), 1254–1308 (C–O); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.7 (s, 1H, C=CH-Ph), 7.17–7.20 (d, 2H, Ph, ³*J* = 8.1 Hz), 7.35–7.37 (d, 2H, Ph, ³*J* = 8.1 Hz), 4.27–4.39 (2q, 4H, 2OCH₂CH₃, ³*J* = 7.12 Hz), 1.29–1.36 (2t, 6H, 2OCH₂CH₃, ³*J* = 7.19 Hz), 2.25 (s, 3H, CH₃-Ph); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.95–163.8 (2C=O), 142.15 (CH₃-Ph-CH=), 141.16 (C_{quat}, CCH₃Ph), 129.55 (2C_{meta}), 130.1 (C_{quat}, para/CH₃), 129.58 (2C_{ortho}), 125.19 (C=C-(CO₂Et)₂), 61.6–61.5 (2OCH₂CH₃), 21.4 (CH₃Ph); 14.1–13.9 (2OCH₂CH₃); SM (IE): Calc. for [M]⁺ C₁₅H₁₈O₄: 262.04. [M+H]⁺ (*m/z*) = 263 (100%).

4.2.7. 2-(4-Trifluoromethyl-benzylidene)-malonic acid diethyl ester (7)

Yield: 77%; R_f = 0.81 (ether/hexane: 1/1); IR (KBr, ν cm^{-1}): 2905–2987 (CH), 1728 (C=O), 1593–1631 (C=C), 1252–1312 (C–O); ^1H NMR (300 MHz, CDCl_3) δ ppm: 7.57 (s, 1H, C=CHPh), 7.53–7.50 (d, 2H_{ortho}, Ph, 3J = 9 Hz), 7.47–7.44 (d, 2H_{meta}, Ph, 3J = 9 Hz), 4.27–4.31 (2q, 4H, 2OCH₂CH₃, 3J = 7.19 Hz), 1.28–1.31 (2t, 6H, 2OCH₂CH₃, 3J = 7.19 Hz); ^{13}C NMR (3000 MHz, CDCl_3) δ ppm: 165.88–163.52 (2C=O), 140.05 (CF₃PhCH=), 136.46 (C_{quat}, CF₃Ph), 129.07 (2C_{meta}), 131.01 (C_{quat}, para/CF₃), 129.82 (2C_{ortho}), 125.92 (C=C(CO₂Et)₂), 61.81–61.57 (2OCH₂CH₃), 77.52 (CF₃Ph), 13.51–13.61 (2OCH₂CH₃); SM (IE): Calc. for [M]⁺ C₁₅H₁₅O₄F₃: 316.02. [M + H]⁺ (m/z) = 317 (100%).

4.2.8. Ethyl 2-cyano-3-phenylacrylate (E) (8)

Yield: 80%; R_f = 0.64 (ether/hexane: 1/1); mp: 91 °C; IR (KBr, ν cm^{-1}): 2900–3068 (CH), 1721.76 (C=O), 1605–1443 (C=C), 1252–1292 (C–O); ^1H NMR (300 MHz, CDCl_3) δ ppm: 8.22 (s, 1H, C=CH–Ph), 7.47–7.79 (m, 5H, Ph), 4.33–4.4 (2q, 2OCH₂CH₃, 3J = 7.2 Hz), 1.35–1.40 (2t, 2OCH₂CH₃, 3J = 7.1 Hz); ^{13}C NMR (300 MHz, CDCl_3) δ ppm: 162.39 (C=O), 154.93 (Ph–CH=C), 115.44 (C=N), 131.48 (C_{quat}, Ph), 133.27 (2C_{tert,meta}), 131.03 (C_{tert,para}), 129.26 (2C_{tert,ortho}), 103.06 (C_{quat}, =C(CO₂Et)), 62.68 (C, OCH₂CH₃), 14.14 (C, OCH₂CH₃).

4.2.9. Ethyl 2-cyano-3-(4-chlorophenyl) acrylate (E) (9)

Yield: 86%; R_f = 0.72 (ether/hexane: 1/1); mp: 125 °C; IR (KBr, ν cm^{-1}): 2893–3024 (CH); 1724.24 (C=O), 1598–1467 (C=C), 1248–1311 (C–O); ^1H NMR (300 MHz, CDCl_3) δ ppm: 8.21 (s, 1H, C=CH–Ph), 7.16–8.05 (m, 4H, Ph), 4.33–4.40 (q, 2H, OCH₂CH₃, 3J = 7.20 Hz), 1.35 (t, 3H, OCH₂CH₃, 3J = 7.20 Hz); ^{13}C NMR (300 MHz, CDCl_3) δ ppm: 162.38 (C=O), 153.49 (Cl–Ph–CH=C), 115.45 (C=N), 127.87 (C_{quat}, C–Cl–Ph), 133.54 (2C_{meta}), 133.66 (C_{quat}, para/Cl), 116.85 (2C_{ortho}), 102.54 (C=C–(CO₂Et)), 62.79 (OCH₂CH₃), 14.15 (OCH₂CH₃).

4.2.10. Ethyl 2-cyano-3-(4-methoxyphenyl) acrylate (E) (10)

Yield: 83%; R_f = 0.63 (ether/hexane: 1/1); mp: 114 °C; ^1H NMR (300 MHz, CDCl_3) δ ppm: 8.18 (s, 1H, C=CH–Ph), 7.33–8.03 (m, 4H, Ph), 4.2–4.46 (q, 2H, OCH₂CH₃, 3J = 7.20 Hz), 2.35 (s, 3H, CH₃–OPh), 1.35–1.41 (2t, 6H, 2CH₂–CH₃, 3J = 7.20 Hz); ^{13}C NMR (300 MHz, CDCl_3) δ ppm: 163.33 (C=O), 154.25 (CH₃O–Ph–CH=C), 115.45 (C=N), 127.87 (C_{quat}, –CH₃–OPh), 132.43 (2C_{meta}), 131.86 (C_{quat}, para/OCH₃), 119.41 (2C_{ortho}), 101.83 (C=C–(CO₂Et)), 61.42 (OCH₂CH₃), 14.03 (OCH₂–CH₃).

4.2.11. Ethyl 2-cyano-3-(4-dimethylaminophenyl) acrylate (E) (11)

Yield: 94%; R_f = 0.75 (ether/hexane: 1/1); mp: 93 °C; IR (KBr, ν cm^{-1}): 2832–2936 (CH), 1702 (C=O), 1565–1610 (C=C), 1271–1296 (C–O); ^1H NMR (300 MHz, CDCl_3) δ ppm: 8.08 (s, 1H, C=CH–Ph), 6.69–7.96 (m, 4H, Ph), 4.31–4.38 (q, 2H, OCH₂CH₃, 3J = 7.20 Hz), 3.11 (s, 6H, N(CH₃)₂), 1.36–1.41 (2t, 3H, OCH₂CH₃, 3J = 7.20 Hz); ^{13}C NMR (300 MHz, CDCl_3) δ ppm: 164.26 (C=O), 154.50 (NMe₂–Ph–CH=), 117.53 (C=N), 154.11 (C_{quat}, NMe₂–Ph), 111.50 (2C_{meta}), 119.42 (C_{quat}, para/NMe₂), 134.02 (2C_{ortho}), 94.16 (C=C–(CO₂Et)), 61.85 (OCH₂–CH₃), 39.98 (CH₃–

NPh) 14.28 (OCH₂CH₃); SM(IE): C₁₄H₁₆O₂N₂: [M]⁺ (m/z) = 244 (100%).

4.2.12. Ethyl 2-cyano-3-(4-methylphenyl) acrylate (E) (12)

Yield: 88%; R_f = 0.61 (ether/hexane: 1/1); mp: 112 °C; ^1H NMR (300 MHz, CDCl_3) δ ppm: 8.23 (s, 1H, C=CH–Ph), 2.45 (s, 3H, CH₃–Ph), 7.28–7.93 (m, 4H, Ph), 4.35–4.43 (q, 2H, 2OCH₂CH₃, 3J = 7.20 Hz), 1.38–1.43 (2t, 6H, 2OCH₂CH₃, 3J = 7.20 Hz); ^{13}C NMR (300 MHz, CDCl_3) δ ppm: 162.78 (C=O), 154.99 (pCH₃–Ph–CH=), 115.78 (C=N), 128.90 (C_{quat}, C–pCH₃–Ph), 130.04 (2C_{meta}), 131.26 (C_{quat}, para/CH₃), 130.04 (2C_{ortho}), 101.61 (C=C–(CO₂Et)), 62.59 (OCH₂–CH₃), 14.18 (OCH₂CH₃), 21.87 (CH₃–Ph); SM (IE): C₁₃H₁₃O₂N: [M]⁺ (m/z) = 215 (100%). [M–OEt]⁺ (m/z) = 170.

4.2.13. Ethyl 2-cyano-3-(4-fluorophenyl) acrylate (E) (13)

Yield: 64%; R_f = 0.73 (ether/hexane: 1/1); mp: 123 °C; IR (KBr, ν cm^{-1}): 2900–3068 (CH), 1721 (C=O), 1572–1605 (C=C), 1252–1299 (C–O); ^1H NMR (300 MHz, CDCl_3) δ ppm: 8.25 (s, 1H, C=CH–Ph), 7.46–7.96 (m, 4H, Ph), 4.36–4.43 (q, 2H, OCH₂CH₃, 3J = 7.20 Hz), 1.39–1.43 (2t, 6H, 2OCH₂CH₃, 3J = 6.90 Hz); ^{13}C NMR (300 MHz, CDCl_3) δ ppm: 162.22 (C=O), 153.36 (p-F–Ph–CH=C), 115.25 (C=N), 139.58 (C_{quat}, –F–CPh), 129.68 (2C_{meta}), 129.90 (C_{quat}, para/F), 132.19 (2C_{ortho}), 103.5 (C=C–(CO₂Et)), 62.86 (OCH₂CH₃), 14.14 (OCH₂CH₃).

4.3. General procedure for the synthesis of compounds (14)–(35)

To a solution of the substituted 2-arylidene malonic acid diethyl esters (1)–(13) (5 mmol) in water (25 mL) was added (6 mmol) of the respective secondary amines (morpholine; 3,5-dimethyl-1H-pyrazole; 4-bromo-3,5-dimethyl-pyrazole; piperidine; pyrrolidine; pyrazole; ethylbenzylamine; dibenzylamine and methylbenzylamine) in the presence or absence of acetic acid (0.1 mol%) and the stirring was continued at room temperature until the complete consumption of the starting material as indicated by TLC. After removing solvent, the crude products were dissolved in diethyl ether (2 × 20 mL) and washed with water until the pH became neutral. The organic solvent was dried over sodium sulphate and then evaporated to give the respective yellow oils which then purified by recrystallisation in (hexane/ether: 2/1) mixture. We have obtained pure compounds as white crystals (14)–(35).

4.3.1. 2-[(Phenyl)-piperidin-1-yl-methyl]-malonic acid diethyl ester (14)

White crystals; Yield: 80%; R_f = 0.72 (ether/hexane: 1/1); mp: 68 °C; IR (KBr, ν cm^{-1}): 2848–2974 (C–H, Ph), 2754–2800 (C–H, aliph), 1702–1740 (C=O), 1514–1450 (C=C), 1313–1257 (C–O); ^1H NMR (300 MHz, CDCl_3) δ ppm: 1.00 (t, 3H, OCH₂CH₃, 3J = 7.1 Hz), 1.26 (m, 2H, –C³H₂–, pr), 1.35 (t, 3H, OCH₂CH₃, 3J = 7.1 Hz), 1.50 (m, 4H, 2C²H₂, pr), 2.20 (s large, 2H, C¹H₂, pr), 2.59 (s large, 2H, C¹H₂, pr), 4.02 (dq, 2H_{AB}, O–CH₂–CH₃, $^2J_{A-B}$ = 10.7 Hz, 3J = 6.9 Hz), 4.23 (d, 1H, C²H–(CO₂Et)₂, 3J = 12.1 Hz), 4.33 (dq, 2H, OCH₂CH₃, J_{A-B} = 0.2 Hz, 3J = 7.1 Hz), 4.43 (d, 1H, Ph–C³H, 3J = 12 Hz), 7.15–7.34 (m, 5H, Ph); ^{13}C NMR (300 MHz, CDCl_3) δ ppm: 167.22–168.04 (2C=O), 133.93 (C_{quat}, Ph), 128.69 (2C_{tert,ortho}, Ph), 127.80 (C_{tert,para}, Ph),

127.53 (C_{tert,meta}, Ph), 69.15 (C_{tert}, PhC²H), 61.30–61.15 (2C, 2OCH₂CH₃), 54.96 (C_{tert}, C²H(CO₂Et)₂), 50.55 (2C, 2C¹H₂, pr), 26.50 (2C, 2C²H₂, pr), 24.40 (C, C³H₂, pr), 14.30–13.75 (2C, 2OCH₂CH₃); SM (IE): [M]⁺ C₁₉H₂₇NO₄: 333.19; [M+H]⁺ (*m/z*) = 334 (35%); 174 (100%); Element. analysis: Calc. C₁₉H₂₇NO₄: %C = 68.46; %H = 8.40; %N = 4.20. Found: %C = 67.89; %H = 7.89; %N = 4.22.

4.3.2. 2-(Phenyl-pyrazol-1-yl-methyl)-malonic acid diethyl (15)

White crystals; Yield: 76%; R_f = 0.45 (ether/hexane: 1/1); mp: 89 °C; IR (KBr, ν cm⁻¹): 2896–2985 (CH), 1748 (C=O), 1514–1595 (C=C), 1292–1308 (C–O), 1175, 1139, 1013, 866, 753, 440; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.30–7.46 (m, 4H, arom, ³J = 8.35 Hz), 6.20 (t, 1H, C⁴Pz, ³J = 2 Hz), 7.5 (d, 2H, C³H and C⁵HPz, ³J = 14.4 Hz), 5.85 (d, 1H, PhC³H, ³J = 11.36 Hz), 4.80 (d, 1H, C²H(CO₂Et)₂, ³J = 11.11 Hz), 3.95 (dq, 2H_{AB}, OCH₂CH₃, J_{AB} = 14.30 Hz, ³J = 7.11 Hz), 4.12 (dq, 2H_{AB}, OCH₂CH₃, J_{AB} = 14.30 Hz, ³J = 7.11 Hz), 1.15 (t, 3H, OCH₂CH₃, ³J = 7.13 Hz), 1.01 (t, 3H, OCH₂CH₃, ³J = 7.13 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.37 (C=O), 166.61 (C=O), 137.15 (C_{quat}, Ph), 128.62 (C_{tert}, 2C_{meta/arm}, Ph), 129.76 (C_{tert}, 2C_{ortho/arm}, Ph), 139.56 (C_{tert}, C⁵–Pz), 128.67 (C_{tert}, C³–Pz), 105.71 (C_{tert}, C⁴H, Pz), 61.87–61.76 (C_{sec}, 2CH₂, ester), 64.22 (C_{tert}, C³HPh), 57.33 (C_{tert}, C²H(CO₂Et)₂), 13.87 (C, OCH₂CH₃), 13.69 (C, OCH₂CH₃); SM (IE): [M]⁺ C₁₇H₂₀O₄: 316, 35; [M+H]⁺ (*m/z*) = 317, [M–CH(CO₂Et)₂]⁺ (*m/z*) = 157 (100%); Element. analysis: Calc. C₁₇H₂₀O₄: %C = 64.54; %H = 6.37; %N = 8.8. Found: %C = 67.37; %H = 6.34; %N = 8.56.

4.3.3. 2-[(Phenyl)-(3,5-dimethyl-pyrazol-1-yl)-methyl]-malonic acid diethyl ester (16)

White crystals; Yield: 76%; R_f = 0.69 (ether/hexane: 1/1); mp: 88 °C; IR (KBr, ν cm⁻¹): 2868–2974 (C–H), 1747–1719 (C=O), 1586–1554 (C=C), 1460–1419 (C=N), 1269–1264 (C–O); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.45–7.25 (m, 5H, Ph), 5.78 (d, 1H, Ph–C³H, ³J = 11.2 Hz), 5.74 (s, 1H, H⁴, Pz), 4.9 (d, 1H, PhC³HC²H, ³J = 11.4 Hz), 4.16–3.99 (2q, 2H, OCH₂CH₃, ³J = 7.3 Hz), 3.97 (q, 2H, OCH₂CH₃, ³J = 7.1 Hz), 2.25 (s, 1H, C³H₃, Pz), 2.21 (s, 1H, C⁵H₃, Pz), 1.17 (t, 3H, OCH₂CH₃, ³J = 7.1 Hz), 0.98 (t, 3H, OCH₂CH₃, ³J = 7.1 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.90–166.85 (2C=O), 147.3 (C_{quat}, C⁵, Pz), 139.30 (C_{quat}, Ph), 137.30 (C_{quat}, C³, pyrazol), 128.50/128.3/127.93 (5C, Ph), 105 (C_{tert}, C²H, Pz), 61.57 (2C, 2OCH₂CH₃), 60.35 (C_{tert}, PhC³HC²H), 57.52 (C_{tert}, Ph–C³HC²H), 13.87 (C, C⁵H₃, Pz), 13.67 (C, C³H₃, Pz), 13.64–10.06 (2C, 2OCH₂CH₃); SM (IE): Calc. [M]⁺ C₁₉H₂₄N₂O₄: 344.17. Found [M+H]⁺ (*m/z*) = 345.28 (11%), 83 (100%); Element. analysis: Calc. C₁₉H₂₄N₂O₄: %C = 66.27; %H = 6.97; %N = 8.13. Found: %C = 65.71; %H = 5.80; %N = 8.78.

4.3.4. 2-[(Phenyl)-3,5-dimethyl-pyrazol-1-yl-methyl]-malonic sodium (16')

White powder; Yield: 95%; R_f = 0 (ether/hexane: 1/1); mp > 260 °C; IR (KBr, ν cm⁻¹): 2900 (CH); 1583 (C=O), 1497 (C=C), 1455 (C=N), 1326–1250 (C–O); ¹H NMR (300 MHz, D₂O) δ ppm: 7.15–7.32 (m, 5H, Ph), 5.68 (d, 1H, Ph–C³H, ³J = 11.2 Hz), 5.72 (s, 1H, H², Pz), 4.23 (d, 1H, PhC³HC²H, ³J = 11.4 Hz), 1.99 (s, 1H, C¹H, Pz), 2.25 (s, 1H, C³H, Pz); ¹³C NMR (300 MHz, D₂O) δ ppm: 175.57 (C=O), 175.29 (C=O), 148.51 (C_{quat}, C¹, Pz), 141.10 (C_{quat},

Ph), 138.86 (C_{quat}, C³, Pz), 128.65 (C_{meta}, 2H, Ph), 127.92 (C_{ortho}, 2H, Ph), 127.43 (C_{para}, 1H, Ph), 104.72 (C_{tert}, C²H, Pz), 62.95 (C_{tert}, PhC³HC²H), 61.33 (C_{tert}, Ph–C³HC²H), 12.21 (C, C¹H₃, Pz), 10.67 (C, C³H₃, Pz).

4.3.5. 2-[(Phenyl)-3,5-dimethyl-pyrazol-1-yl-methyl]-malonic acid (16'')

White powder; Yield: 83%; mp: 154 °C; R_f = 0.22 (ether/hexane: 1/1); IR (KBr, ν cm⁻¹): 2918–3068 (CH), 1705 (C=O), 1555–1500 (C=C), 1459–1484 (C=N), 3406 (OH), 1343–1273 (C–O), 1146, 104, 951; ¹H NMR (300 MHz, acetone) δ ppm: 7.27–7.44 (m, 5H, Ph), 5.89 (d, 1H, Ph–C³H, ³J = 11.2 Hz), 5.83 (s, 1H, H², Pz), 4.78 (d, 1H, PhC³HC²H, ³J = 11.4 Hz), 4.19 (s, OH, CO₂H), 2.15 (s, 1H, C¹H, Pz), 2.26 (s, 1H, C³H, Pz); ¹³C NMR (300 MHz, acetone) δ ppm: 167.07 (C=O), 167.43 (C=O), 146.73 (C_{quat}, C¹, pyrazol), 140.73 (C_{quat}, Ph), 139.96 (C_{quat}, C³, Pz), 127.58–130.35 (C_{tert}, 5CH, Ph), 105.15 (C_{tert}, C²H, pyrazol), 59.75 (C_{tert}, PhC³HC²H), 57.75 (C_{tert}, Ph–C³HC²H), 12.72 (C, C¹H₃, Pz), 10.08 (C, C³H₃, Pz).

4.3.6. 2-[(Phenyl)-dibenzyl amino-1-yl-methyl]-malonic acid diethyl ester (17)

White crystals; Yield: 76%; R_f = 0.53 (ether/hexane: 1/1); mp: 119 °C; IR (KBr, ν cm⁻¹): 2883–2930 (C–H), 1747 (C=O), 1584–1600 (C=C), 1323–1252 (C–O), 1157, 1110, 1037; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.23–7.45 (m, 15H, arom), 4.59 (d, 1H, PhC³H, ³J = 12.0 Hz), 4.44 (d, 1H, C²H(CO₂Et)₂, ³J = 12.0 Hz), 3 (d, 2H, CH₂Ph, ³J = 13.5 Hz), 3.98 (d, 2H, CH₂Ph, ³J = 13.5 Hz), 3.94 (dq, 2H_{AB}, ²J_{AB} = 14.29 Hz, ³J = 7.13 Hz), 4.22 (dq, 2H_{AB}, J_{AB} = 14.29 Hz, ³J = 7.13 Hz), 1.28 (t, 3H, OCH₂CH₃, ³J = 7.11 Hz), 0.95 (t, 3H, OCH₂CH₃, ³J = 7.11 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 167.51–166.86 (2C=O), 139.05 (C_{quat}, C, Ph), 133.79 (2C_{quat}, 2Ph), 129.27–127.0 (C_{tert}, Ph), 61.79 (C_{tert}, C³H–Ph), 61.60 (C, OCH₂CH₃, ester), 61.13 (C, OCH₂CH₃, ester), 55.39 (C_{tert}, C²H(CO₂Et)₂), 53.94 (2C_{sec}, 2CH₂N), 13.92–13.65 (2C, 2OCH₂CH₃); SM (IE): Calc. [M]⁺ C₂₈H₃₁NO₄: 445.55. Found [M+H]⁺ (*m/z*) = 446; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 286 (100%); Element. analysis: Calc. C₂₈H₃₁NO₄: %C = 75.48; %H = 7.01; %N = 3.14. Found: %C = 75.46; %H = 7.02; %N = 3.12.

4.3.7. 2-[(Phenyl)-benzyl methyl-1-yl-methyl]-malonic acid diethyl ester (18)

White crystals; Yield: 78%; R_f = 0.45 (ether/hexane: 1/1); mp: 107 °C; IR (KBr, ν cm⁻¹): 2860–2984 (C–H), 1745 (C=O), 1216–1301 (C–O), 1584–1601 (C=C), 1138, 1021; ¹H NMR (300 MHz, CDCl₃) δ ppm: 1.01 (t, 3H, OCH₂CH₃, ³J = 7.2 Hz), 1.33 (t, 3H, OCH₂CH₃, ³J = 7.2 Hz), 3.25 (d, 1H, CH₂Ph, ³J = 13.5 Hz), 3.5 (d, 1H, CH₂Ph, ³J = 13.2 Hz), 4.32 (d, H, C²H(CO₂Et)₂, ³J = 12.20 Hz), 4.65 (d, H, Ph–C³H, ³J = 12.15 Hz), 4.01 (dq, 2H_{AB}, OCH₂CH₃, ²J_{AB} = 14.34 Hz, ³J = 7.06 Hz), 4.35 (dq, 2H_{AB}, OCH₂CH₃, ²J_{AB} = 14.34 Hz, ³J = 7.06 Hz), 2.05 (s, 3H, CH₃N), 7.2–7.4 (m, 10H, Ph); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 167.93 (C=O), 167.97 (C=O), 133.4 (C_{quat}, C–(Ph)), 132.6 (C_{quat}, CPhCH₂), 126.91–128.03 (C_{tert}, 10CH arom), 67.47 (C_{tert}, C³HPh); 61.24–61.3 (2C, 2CH₂CH₃, ester), 55.39 (C_{tert}, C²H–(CO₂Et)), 58.70 (C_{sec}, C¹H₂N), 36.94 (C_{tert}, CH₃N), 14.15–13.73 (2C, 2OCH₂CH₃); SM (IE): Calc. [M]⁺ C₂₈H₃₀NO₄Cl: 369.45. Found [M+H]⁺ (*m/z*) = 370;

$[M-CH(CO_2Et)_2]^+$ (m/z) = 159 (100%); Element. analysis: Calc. $C_{28}H_{30}NO_4Cl$: %C = 71.52; %H = 7.37; %N = 3.79. Found: %C = 71.48; %H = 7.35; %N = 3.81.

4.3.8. 2-[(Benzyl-ethyl-amine)-phenyl]-methyl]-malonic acid diethyl ester (19)

White crystals; Yield: 82%; R_f = 0.51 (ether/hexane: 1/1); mp: 92 °C; IR (KBr, ν cm^{-1}): 2872–2935 (CH), 1731 (C=O), 1490–1594 (C=C), 1290–1303 (C–O), 1179, 1012; 1H NMR (300 MHz, $CDCl_3$) δ ppm: 7.18–7.38 (m, 10H, 2Ph), 4.65 (d, 1H, PhC^3H , 3J = 12.1 Hz), 4.42 (d, 1H, $C^2H(CO_2Et)_2$, 3J = 12.0 Hz), 3.98 (d, 1H, CH_2Ph , 3J = 13.80 Hz), 2.95 (d, 1H, NCH_2CH_3 , 3J = 13.80 Hz), 2.1 (dq, 1H_{AB}, NCH_2CH_3 , J_{AB} = 12.94 Hz, 3J = 7.2 Hz), 2.55 (dq, 1H_{AB}, NCH_2Ph , $^2J_{AB}$ = 12.94 Hz, 3J = 7.2 Hz), 4.0 (dq, 2H_{AB}, OCH_2CH_3 , J_{AB} = 14.1 Hz, 3J = 7.0 Hz), 4.3 (dq, 2H_{AB}, OCH_2CH_3 , $^2J_{AB}$ = 14.1 Hz, 3J = 7.0 Hz), 1.04 (t, 3H, NCH_2CH_3 , 3J = 7.2 Hz), 1.1 (t, 3H, OCH_2CH_3 , 3J = 7.2 Hz), 1.45 (t, 3H, OCH_2CH_3 , 3J = 7.2 Hz); ^{13}C NMR (300 MHz, $CDCl_3$) δ ppm: 166.91–167.47 (2C=O), 139.42 (C_{quat} , C^- , Ph), 133.06 (C_{quat} , CH_2Ph), 126.91–130.19 (C_{tert} , 2Ph), 61.32–61.60 (C_{sec} , $2OCH_2CH_3$), 61.83 (C_{tert} , C^3HPh), 55.50 (C_{tert} , $C^2H(CO_2Et)_2$), 43.41 (C_{sec} , NCH_2CH_3), 55.32 (C_{sec} , NCH_2Ph), 13.40 (C_{tert} , NCH_2CH_3), 13.77 (C_{tert} , OCH_2CH_3), 14.06 (C_{tert} , OCH_2CH_3); SM (IE): Calc. $[M]^+$ $C_{23}H_{29}NO_4$: 383.16. Found $[M+H]^+$ (m/z) = 384; $[M-CH(CO_2Et)_2]^+$ (m/z) = 224 (100%); Element. analysis: Calc. $C_{23}H_{29}NO_4$: %C = 72.04; %H = 7.63; %N = 3.65. Found: %C = 72.0; %H = 7.63; %N = 3.64.

4.3.9. 2-[(4-Chlorophenyl)-morpholin-4-yl-methyl]-malonic acid diethyl ester (20)

White crystals; Yield: 96%; R_f = 0.55 (ether/hexane: 1/1); mp: 68–69 °C; IR (KBr, ν cm^{-1}): 2935–2985 (C–H, 4-Cl-Ph), 2826–2887 (C–H), 1747 (C=O), 1712 (C=O), 1590–1489 (C=C), 1306–1258 (C–O); 1H NMR (300 MHz, $CDCl_3$) δ ppm: 7.35 (d, 2H, ortho, 3J = 8.30 Hz), 7.12 (d, 2H, meta, 3J = 8.30 Hz), 4.25–4.39 (m, 3H, OCH_2CH_3 + PhC^3H), 4.20 (d, 1H, $C^2H(CO_2Et)_2$, 3J = 10.3 Hz), 3.90–4.07 (m, 2H, OCH_2CH_3), 3.93 (s, 4H, $C^2H_2OC^2H_2$), 2.53 (s, 2H, C^1H_2), 2.30 (s, 2H, C^1H_2), 1.06 (t, 3H, OCH_2CH_3 , 3J = 7.1 Hz), 1.06 (t, 3H, OCH_2CH_3 , 3J = 7.1 Hz); ^{13}C NMR (300 MHz, $CDCl_3$) δ ppm: 167.6 (2C=O), 134.8 (C_{quat} , p-Cl-Ph), 131.8 (C_{quat} , Ph, para/Cl), 130 (C_{tert} , 2C-ortho, Ph), 128.4 (C_{tert} , 2C-meta, Ph), 68.0 (C_{tert} , C^3H-Ph), 67.1 (2C, $2C^2H_2O$, mor), 61.6 (C, OCH_2CH_3), 61.5 (C, OCH_2CH_3), 54.6 (C_{tert} , $C^2H(CO_2Et)_2$), 49.5 (2C, $2C^1H_2N$, mor), 14.3 (C, OCH_2CH_3), 13.8 (C, OCH_2CH_3); SM (IE): Calc. $[M]^+$ $C_{18}H_{24}ClNO_5$: 369.13. Found $[M+H]^+$ (m/z) = 370 (15%); $[M-CH(CO_2Et)_2]^+$ (m/z) = 210 (100%); Element. analysis: Calc. $C_{18}H_{24}NO_5Cl$: %C = 58.53; %H = 6.50; %N = 3.79. Found: %C = 58.60; %H = 6.71; %N = 4.03.

4.3.10. 2-[(4-Chlorophenyl)-pyrrolidin-1-yl-methyl]-malonic acid diethyl ester (21)

White crystals; Yield: 73%; R_f = 0.68 (ether/hexane: 1/1); mp: 79 °C; IR (KBr, ν cm^{-1}): 2969 (C–H, Ph), 2674–2806 (C–H), 1747–1720 (C=O), 1592–1464 (C=C), 1329–1256 (C–O); 1H NMR (300 MHz, $CDCl_3$) δ ppm: 7.29–7.29 (m, 2H, Ph), 7.14–7.18 (m, 2H, Ph), 4.5 (d, 1H, PhC^3H , 3J = 11.40 Hz), 4.09 (d, 1H, $C^2H(CO_2Et)_2$, 3J = 11.40 Hz), 4.25 (q, 2H, OCH_2CH_3 , 3J = 7.1 Hz), 3.95 (m, 2H, OCH_2CH_3), 2.49 (m,

2H, $N-C^1H_2$, pyr), 2.35 (m, 2H, NC^1H_2 , pyr), 1.59 (m, 4H, $2C^1H_2C^2H_2$, pyr), 1.30 (t, 3H, OCH_2CH_3 , 3J = 7.1 Hz), 1.03 (t, 3H, OCH_2CH_3 , 3J = 7.1 Hz); ^{13}C NMR (300 MHz, $CDCl_3$) δ ppm: 166.97–167.88 (2C=O), 133.35 (C_{quat} , CCl, Ph), 133.22 (C_{quat} , Ph, para/Cl), 130.35 (C_{tert} , 2C_{ortho}, Ph), 128.05 (C_{tert} , 2C_{meta}, Ph), 64.05 (C_{tert} , C^3HPh), 61.40 (C, OCH_2CH_3), 61.30 (C, OCH_2CH_3), 56.50 (C_{tert} , $C^2H(CO_2Et)_2$), 48.41–46.88 (2C, $2C^1H_2N$, pyr), 22.84 (2C, $2C^1H_2C^2H_2$, pyr), 13.91–14.12 (2C, $2OCH_2CH_3$); SM (IE): Calc. $[M]^+$ $C_{18}H_{24}ClNO_4$: 353.14. Found $[M+H]^+$ (m/z) = 354 (18%); $[M-CH(CO_2Et)_2]^+$ (m/z) = 194 (100%); $[M-pyrrol]^+$ (m/z) = 283; Element. analysis: Calc. $C_{18}H_{24}ClNO_4$: %C = 62.12; %H = 7.08; %N = 3.18. Found: %C = 62.10; %H = 7.28; %N = 4.04.

4.3.11. 2-(4-Chlorophenyl)-pyrazol-1-yl-methyl]-malonic acid diethyl ester (22)

White crystals; Yield: 71%; R_f = 0.65 (ether/hexane: 1/1); mp: 89 °C; IR (KBr, ν cm^{-1}): 2896–2985 (CH), 1748 (C=O), 1514–1595 (C=C), 1292–1308 (C–O); 1H NMR (300 MHz, $CDCl_3$) δ ppm: 7.28–7.44 (m, 4H, Ph, 3J = 8.68 Hz), 6.20 (t, 1H, Pz, 3J = 2.08 Hz), 7.5 (d, 2H, C^3H , C^5H , Pz, 3J = 14.27 Hz), 5.85 (d, 1H, PhC^3H , 3J = 11.33 Hz), 4.80 (d, 1H, $C^2H(CO_2Et)_2$, 3J = 11.33 Hz), 4.10 (dq, 2H_{AB}, OCH_2CH_3 , J_{AB} = 14.32 Hz, 3J = 7.11 Hz), 4.01 (dq, 2H_{AB}, OCH_2CH_3 , J_{AB} = 14.32 Hz, 3J = 7.11 Hz), 2.25 (s, 3H, CH_3 , Pz), 2.20 (s, 3H, CH_3 , Pz), 1.13 (t, 3H, OCH_2CH_3 , 3J = 7.11 Hz), 1.04 (t, 3H, OCH_2CH_3 , 3J = 7.11 Hz); ^{13}C NMR (300 MHz, $CDCl_3$) δ ppm: 166.36 (C=O), 166.26 (C=O), 147.65 (C_{quat} , Pz), 139.3 (C_{quat} , Pz), 135.7 (C_{quat} , CCl, Ph), 134.62 (C_{quat} , Ph, para/Cl), 129.83 (C_{tert} , 2C_{meta}/bras, Ph), 128.7 (C_{tert} , 2C_{ortho}/bras, Ph), 129.27 (C_{tert} , C^3 , Pz), 105.45 (C_{tert} , C^4H , Pz), 61.75–61.70 (C_{sec} , $2OCH_2CH_3$), 59.55 (C_{tert} , C^3HPh), 57.45 (C_{tert} , $C^2H(CO_2Et)_2$), 13.87 (C, OCH_2CH_3), 13.75 (C, OCH_2CH_3), 13.66 (C, CH_3 , Pz), 10.95 (CH_3 , Pz); SM (IE): Calc. $[M]^+$ $C_{17}H_{19}N_2O_4Cl$: 350.5. Found $[M+H]^+$ (m/z) = 351 (15%); $[M-CH(CO_2Et)_2]^+$ (m/z) = 191 (100%); $[M-Pz]^+$ (m/z) = 283 (21%); Element. analysis: Calc. $C_{18}H_{24}ClNO_4$: %C = 64.55; %H = 6.32; %N = 8.86. Found: %C = 64.46; %H = 6.62; %N = 9.06.

4.3.12. 2-[(4-Chlorophenyl)-piperidin-1-yl-methyl]-malonic acid diethyl ester (23)

White crystals; Yield: 67%; R_f = 0.65 (ether/hexane: 1/1); mp: 65 °C; IR (KBr, ν cm^{-1}): 1755–1737 (C=O), 2973–2848 (C–H), 1493–1452 (C=C), 1312–1257 (C–O); 1H NMR (300 MHz, $CDCl_3$) δ ppm: 1.05 (t, 3H, OCH_2CH_3 , 3J = 7.10 Hz), 1.26 (m, 2H, C^3H_2 , 3J = 5.9 Hz), 1.35 (t, 3H, OCH_2CH_3 , 3J = 7.10 Hz), 1.48 (m, 4H, $2C^2H_2$), 2.16 (m, 2H, NC^1H_2), 2.46 (m, 2H, NC^1H_2), 4.16 (d, H, $C^2H(CO_2Et)_2$, 3J = 12.10 Hz), 4.35 (d, H, PhC^3H , 3J = 12.20 Hz), 4.02 (dq, 2H_{AB}, OCH_2CH_3 , J_{AB} = 11.3 Hz), 4.30 (dq, 2H_{AB}, OCH_2CH_3 , J_{AB} = 10.7 Hz), 7.1 (d, 2H, arom-ortho, 3J = 10.7 Hz), 7.32 (d, 2H, arom-meta, 3J = 10.9 Hz); ^{13}C NMR (300 MHz, $CDCl_3$) δ ppm: 167.71 (C=O), 167.03 (C=O), 133.4 (C_{quat} , ClCPh), 132.6 (C_{quat} , para/Cl), 129.9 (C_{tert} , 2C_{meta}, Ph), 128.04 (C_{tert} , 2C_{ortho}, Ph), 69.5 (C_{tert} , C^3HPh), 61.4–61.3 (2C, $2OCH_2CH_3$), 54.95 (C_{tert} , $C^2H(CO_2Et)_2$), 50.51 (2C, $2C^1H_2N$), 26.4 (2C, $2C^2H_2CH_2N$), 24.40 (C, $N(CH_2)_2C^3H_2$), 14.3–13.8 (2C, $2OCH_2CH_3$); SM (IE): Calc. $[M]^+$ $C_{19}H_{26}ClNO_4$: 367.16. Found $[M+H]^+$ (m/z) = 368 (16%); $[M-CH(CO_2Et)_2]^+$ (m/z) = 256

(100%); [M–PhCl]⁺ (*m/z*) = 249; Element. analysis: Calc. C₁₉H₂₆ClNO₄: %C = 62.12; %H = 7.08; %N = 3.18. Found: %C = 62.10; %H = 7.28; %N = 3.14.

4.3.13. 2-[(4-Chlorophenyl)-benzylethylamino-methyl]-malonic acid diethyl ester (24)

White crystal; Yield: 84%; *R_f* = 0.56 (ether/hexane: 1/1); mp: 70–72 °C; IR (KBr, ν cm⁻¹): 2808–2985 (CH), 1732 (C=O), 1594–1595 (C=C), 1248–1291 (C–O); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.24–7.37 (m, 4H, PhCl, ³*J* = 8.43 Hz), 7.23–7.1 (m, 5H, Ph, ³*J* = 4.42 Hz), 4.62 (d, 1H, ClPhC³H, ³*J* = 12.30 Hz), 4.24 (d, 1H, C²H(CO₂Et)₂, ³*J* = 12.30 Hz), 2.9 (d, 1H, CH–Ph, ³*J* = 13.80 Hz), 3.9 (d, 1H, CH–Ph, ³*J* = 13.80 Hz), 2.1 (m, 1H, CHCH₃, ³*J* = 12.90 Hz), 2.55 (m, 1H, CHCH₃, ³*J* = 12.90 Hz), 4.01 (dq, 2H_{A–B}, OCH₂CH₃, *J*_{AB} = 14.10 Hz, ³*J* = 7.07 Hz), 4.30 (dq, 2H_{A–B}, OCH₂CH₃, *J*_{AB} = 14.10 Hz, ³*J* = 7.07 Hz), 1.15 (t, 3H, NCH₂–CH₃), 1.30 (t, 3H, OCH₂–CH₃, ³*J* = 7.07 Hz), 1.01 (t, 3H, OCH₂CH₃, ³*J* = 7.07 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.93 (C=O), 167.84 (C–O), 139.41 (C_{quat}, CCl, Ph), 133.54 (C_{quat}, Ph, para/Cl), 130.81 (C_{tert}, 2C_{meta}, Ph–Cl), 128.15 (C_{tert}, 2C_{ortho}, Ph–Cl), 128.28 (C_{tert}, 2C_{meta}, Ph), 128.15 (C_{tert}, 2C_{ortho}, Ph), 126.91 (C_{tert}, 2C_{para}, Ph), 61.75–61.70 (C_{sec}, 2OCH₂CH₃), 61.75 (C_{tert}, C³HPhCl), 55.47 (C_{tert}, C²H(CO₂Et)₂), 14.07 (C_{tert}, 2OCH₂CH₃), 13.79 (C_{tert}, OCH₂CH₃), 13.41 (C_{tert}, NCH₂CH₃), 54.21 (C_{sec}, NCH₂CH₃); SM (IE): Calc. [M]⁺ C₂₃H₂₈ClNO₄: 417.5; [M+H]⁺ (*m/z*) = 418 (12%). Found [M–CH(CO₂Et)₂]⁺ (*m/z*) = 258 (100%); [M–N(CH₂Ph, C₂H₅)]⁺ (*m/z*) = 283; Element. analysis: Calc. C₂₃H₂₈ClNO₄: %C = 66.18; %H = 6.71; %N = 3.35. Found: %C = 65.53; %H = 6.66; %N = 3.55.

4.3.14. 2-[(4-Chlorophenyl)-3,5-dimethyl-pyrazol-1-yl-methyl]-malonic acid diethyl ester (25)

White crystals; Yield: 83%; *R_f* = 0.67 (ether/hexane: 1/1); mp: 83 °C; IR (KBr, ν cm⁻¹): 2981–2935 (CH), 1764 (C=O), 1594–1554 (C=C), 1490–1463 (C=N), 1300–1257 (C–O); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.25–7.44 (m, 4H, Ph, ³*J* = 8.25 Hz), 5.74 (s, 1H, Pz), 5.70 (d, 1H, PhC³H, ³*J* = 11.3 Hz), 4.84 (d, 1H, C²H(CO₂Et)₂, ³*J* = 11.3 Hz), 4.12 (dq, 2H_{A–B}, OCH₂CH₃, *J*_{AB} = 14.3 Hz, ³*J* = 7.2 Hz), 4.0 (dq, 2H_{A–B}, OCH₂CH₃, *J*_{AB} = 14.3 Hz, ³*J* = 7.2 Hz), 2.25 (s, 3H, CH₃, Pz), 2.20 (s, 3H, CH₃, Pz), 5.75 (s, 1H, C⁴, Pz), 1.16 (t, 3H, OCH₂CH₃, ³*J* = 7.1 Hz), 1.04 (t, 3H, OCH₂CH₃, ³*J* = 7.1 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.60 (C=O), 166.75 (C=O), 147.65 (C_{quat}, Pz), 139.3 (C_{quat}, Pz), 138.9 (C_{quat}, CCl, Ph), 134.25 (C_{quat}, Ph, para/Cl), 129.4 (C_{tert}, 2C_{meta}, Ph), 128.7 (C_{tert}, 2C_{ortho}, Ph), 105.45 (C_{tert}, CH, Pz), 61.75–61.70 (C_{sec}, 2OCH₂CH₃), 59.55 (C_{tert}, C³HPh), 57.45 (C_{tert}, C²H(CO₂Et)₂), 13.87 (C_{tert}, OCH₂CH₃), 13.75 (C_{tert}, OCH₂CH₃), 13.66 (C_{tert}, CH₃, Pz), 10.95 (C_{tert}, CH₃, Pz); MS (IE): Calc. [M]⁺ C₁₉H₂₃ClN₂O₄: 378.13. Found [M+H]⁺ (*m/z*) = 379 (17%); [M–CH(CO₂Et)₂]⁺ (*m/z*) = 219 (100%); [M–Pz]⁺ (*m/z*) = 283; Element. analysis: Calc. C₁₉H₂₃ClN₂O₄: %C = 60.31; %H = 6.08; %N = 7.40. Found: %C = 60.43; %H = 6.05; %N = 7.69.

4.3.15. 2-[(4-Chlorophenyl)-dibenzyl amino-1-yl-methyl]-malonic acid diethyl ester (26)

White crystals; Yield: 67%; *R_f* = 0.42 (ether/hexane: 1/1); mp: 112 °C; IR (KBr, ν cm⁻¹): 2811–2980 (CH); 1722 (CO), 1591

(C=C), 1257–1301 (C–O), 1181, 1092, 822, 747, 416; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.24–7.44 (m, 4H, arom, Ph–Cl, ³*J* = 6.60 Hz), 7.23–7.31 (m, 10H, arom, Ph, ³*J* = 4.15 Hz), 4.56 (d, 1H, ClPhC³H, ³*J* = 12.12 Hz), 4.33 (d, 1H, C²H(CO₂Et)₂, ³*J* = 12.12 Hz), 3.0 (d, 1H, 2CHPh, ³*J* = 13.50 Hz), 3.9 (d, 1H, 2CHPh, ³*J* = 13 Hz), 3.98 (dq, 2H_{A–B}, OCH₂CH₃, ²*J*_{AB} = 14.10 Hz, ³*J* = 7.10 Hz), 4.20–4.40 (dq, 2H_{A–B}, OCH₂CH₃, ²*J*_{AB} = 14.11 Hz, ³*J* = 7.10 Hz), 1.30 (t, 3H, OCH₂CH₃, ³*J* = 7.10 Hz), 1.01 (t, 3H, OCH₂CH₃, ³*J* = 7.10 Hz), 1.25 (t, 3H, OCH₂CH₃, ³*J* = 7.10 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.74–167.26 (C=O), 138.71 (C_{quat}, CCl, Ph), 133.68 (C_{quat}, p-Cl–Ph), 130.47 (C_{tert}, 2C_{meta}, p-Cl–Ph), 128.91 (C_{tert}, 2C_{ortho}, p-Cl–Ph), 128.29 (C_{quat}, 2C, 2Ph), 128.34 (C_{tert}, 4C_{meta}, 2Ph), 128.29 (C_{tert}, 4C_{ortho}, 2Ph), 127.15 (C_{tert}, 2C_{para}, 2Ph), 61.73 (C_{sec}, 2OCH₂CH₃), 61.04 (C_{tert}, C³HPhCl), 55.26 (C_{tert}, C²H(CO₂Et)₂), 13.75 (C_{tert}, OCH₂CH₃), 13.92 (C_{tert}, OCH₂CH₃), 61.31 (C_{sec}, 2CH₂Ph); SM (IE): Calc. [M]⁺ C₂₈H₃₀NO₄Cl: 479.99. Found [M+H]⁺ (*m/z*) = 481; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 320 (100%); Element. analysis: Calc. C₂₈H₃₀NO₄Cl: %C = 70.06; %H = 6.30; %N = 2.92. Found: %C = 69.98; %H = 6.27; %N = 2.91.

4.3.17. 2-[(4-Chlorophenyl)-4-bromo-3,5-dimethyl-pyrazol-1-yl-methyl]-malonic acid diethyl ester (27)

White crystals; Yield: 86%; *R_f* = 0.53 (ether/hexane: 1/1); mp: 95 °C; IR (KBr, ν cm⁻¹): 2984–2939 (CH), 1758 (C=O), 1595–1543 (C=C), 1490–1463 (C=N), 1300–1265 (C–O); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.26–7.39 (m, 4H, Ph, ³*J* = 6.30 Hz), 5.78 (d, 1H, PhC³H, ³*J* = 11.3 Hz), 4.83 (d, 1H, C²H(CO₂Et)₂, ³*J* = 11.3 Hz), 4.20 (dq, 2H_{A–B}, OCH₂CH₃, *J*_{AB} = 13.54 Hz, ³*J* = 7.2 Hz), 4.0 (dq, 2H_{A–B}, OCH₂CH₃, *J*_{AB} = 13.54 Hz, ³*J* = 7.2 Hz), 2.24 (s, 3H, CH₃, Pz), 2.18 (s, 3H, CH₃, Pz), 1.13 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 1.02 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.08 (C=O), 167.01 (C=O), 146.29 (C_{quat}, Pz), 137.5 (C_{quat}, Pz), 136.58 (C_{quat}, CCl, Ph), 134.35 (C_{quat}, Ph, para/Cl), 127.88 (C_{tert}, 2C_{meta}, Ph), 128.31 (C_{tert}, 2C_{ortho}, Ph), 94.83 (C_{quat}, C⁴Br, Pz), 61.47–61.70 (C_{sec}, 2OCH₂CH₃), 59.88 (C_{tert}, C³HPh), 56.99 (C_{tert}, C²H(CO₂Et)₂), 13.86 (OCH₂CH₃), 14.08 (OCH₂CH₃), 12.41 (CH₃, Pz), 11.26 (CH₃, Pz); MS (IE): Calc. [M]⁺ C₁₉H₂₂ClN₂O₄Br: 456. Found [M+H]⁺ (*m/z*) = 457; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 297 (100%); [M–pyrazol]⁺ (*m/z*) = 361.

4.3.18. 2-[(4-Trifluoromethyl-phenyl)-pyrrolidin-1-yl-methyl]-malonic acid diethyl ester (28)

White crystals; Yield: 73%; *R_f* = 0.62 (ether/hexane: 1/1); mp: 73 °C; IR (KBr, ν cm⁻¹): 2875–2940 (C–H), 1745 (C=O), 1585–1618 (C=C), 1269–1264 (C–O), 1153, 1112, 1066; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.33 (d, 2H_{ortho}, ³*J* = 8.03 Hz), 7.60 (d, 2H_{meta}, ³*J* = 8.03 Hz), 4.6 (d, 1H, Ph–C³H, ³*J* = 11.25 Hz), 4.13 (d, 1H, PhC³HC²H, ³*J* = 11.25 Hz), 4.3 (dq, 2H_{A–B}, OCH₂CH₃, ²*J*_{AB} = 10.08 Hz, ³*J* = 7.3 Hz), 4.0 (dq, 2H_{A–B}, OCH₂CH₃, ²*J*_{AB} = 10.08 Hz, ³*J* = 7.3 Hz), 2.35 (s, 2H, C¹H₂–pyr), 2.47 (s, 2H, C¹H₂–pyr), 1.6 (m, 4H, C²H, pyr), 1.3 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz); 1.6 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.89–167.75 (C=O), 138.95 (C_{quat}, CF₃Ph), 129.0 (C_{quat}, p-CF₃Ph), 128.11 (C_{tert}, C_{meta}, Ph), 125.90 (C_{tert}, C_{ortho}, Ph), 64.27 (C_{tert}, C³H, Ph), 55.83 [C_{tert}, C²H, CH³=CH²(CO₂Et)₂], 61.93–61.45 (2C,

2OCH₂CH₃), 48.50–47.06 (2C_{sec}, 2C²H, pyr), 22.84 (2C_{sec}, 2C¹H, pyr), 13.66–14.03 (2C_{tert}, 2OCH₂CH₃); SM (IE): Calc. [M]⁺ C₁₉H₂₄NO₄F₃: 387.39. Found [M+H]⁺ (*m/z*) = 388; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 228 (100%); Element. analysis: Calc. C₁₉H₂₄NO₄F₃: %C = 58.91; %H = 6.24; %N = 3.62. Found: %C = 60.01; %H = 6.25; %N = 3.61.

4.3.19. 2-[4-Trifluoromethyl-phenyl]-piperidin-methyl]-malonic acid diethyl (29)

White crystals; Yield: 67%; *R*_f = 0.67 (ether/hexane: 1/1); mp: 92 °C; IR (KBr, ν cm⁻¹): 2875–2938 (CH), 1729 (C=O), 1491–1593 (C=C), 1291–1302 (C–O), 1180, 1011; ¹H NMR (300 MHz, CDCl₃) δ ppm: 1.03 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 1.35 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 1.26 (m, 2H, C³H₂, pip), 1.52 [m, 4H, 2(C²H₂), pip], 2.1 (s, 2H, C¹H₂, pip), 2.51 (s, 2H, C¹H₂, pip), 4.01 (dq, 2H_{AB}, OCH₂CH₃, ²*J*_{AB} = 10.14 Hz, ³*J* = 7.04 Hz), 4.22 (d, 1H, C²H(CO₂Et)₂, ³*J* = 12.11 Hz), 4.30 (dq, 2H, OCH₂CH₃, ²*J*_{AB} = 10.14 Hz, ³*J* = 7.02 Hz), 4.41 (d, 1H, PhC³H, ³*J* = 12.1 Hz), 7.27 (d, 2H_{ortho}, ³*J* = 8.1 Hz), 7.58 (d, 2H_{meta}, ³*J* = 8.1 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.97–166 (2C=O), 129.50 (C_{quat}, arom), 138.17 (C_{quat}, C–CF₃); 129.05 (2C_{tert}, meta, Ph), 124.80 (C_{tert}, ortho, Ph), 54.74 [C_{tert}, PhC²H(CO₂Et)₂], 68.63 (C_{tert}, PhC³H), 61.45–61.35 (2C, 2OCH₂CH₃), 50.54 (2C, 2C¹H₂, pip), 26.38 (2C, 2C²H₂, pip), 24.27 (C, C³H₂, pip), 14.25–13.72 (2C, 2OCH₂CH₃); SM (IE): Calc. [M]⁺ C₂₀H₂₆NO₄F₃: 401.41. Found [M+H]⁺ (*m/z*) = 402; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 242 (100%); Element. analysis: Calc. C₂₀H₂₆NO₄F₃: %C = 59.84; %H = 6.53; %N = 3.49. Found: %C = 59.82; %H = 6.51; %N = 3.47.

4.3.20. 2-[4-Trifluoromethyl-phenyl]-morpholin-methyl]-malonic acid diethyl ester (30)

White crystals; Yield: 96%; *R*_f = 0.67 (ether/hexane: 1/1); mp: 103 °C; IR (KBr, ν cm⁻¹): 2870–2934 (CH), 1730 (C=O), 1491–1593 (C=C), 1291–1304 (C–O), 1181; 1014; ¹H NMR (300 MHz, CDCl₃) δ ppm: 1.33 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 1.01 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 3.54–3.66 (m, 4H, C²H₂, mor), 2.29 (s large, 2H, C¹H₂, mor), 2.53 (s large, 2H, C¹H₂, mor), 4.0 (dq, 2H_{AB}, OCH₂CH₃, ²*J*_{AB} = 14.06 Hz, ³*J* = 7.01 Hz), 4.33 (dq, 2H, OCH₂CH₃, ²*J*_{AB} = 14.06 Hz, ³*J* = 7.01 Hz), 4.25 (d, 1H, C²H(CO₂Et)₂, ³*J* = 12.13 Hz), 4.42 (d, 1H, PhC³H, ³*J* = 12.13 Hz), 7.64 (d, 2H_{ortho}, ³*J* = 8.1 Hz), 7.28 (d, 2H_{meta}, ³*J* = 8.1 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.62–167.42 (2C=O), 130.40 (C_{quat}, Ph), 137.51 (C_{quat}, CCF₃Ph), 125.08 (2C_{tert}, meta-arom), 129.96 (C_{tert}, ortho-arom), 54.49 (C_{tert}, PhC²H(CO₂Et)₂), 68.11 (C_{tert}, PhC³H), 61.62–61.54 (2C, 2OCH₂CH₃), 49.52 (C_{sec}, 2C¹H₂, mor), 67.12 (C_{sec}, 2C²H₂, mor), 14.30–13.17 (C_{tert}, 2OCH₂CH₃); SM (IE): Calc. [M]⁺ C₁₉H₂₄NO₅F₃: 403.39. Found [M+H]⁺ (*m/z*) = 404; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 244 (100%); Element. analysis: Calc. C₁₉H₂₄NO₅F₃: %C = 56.57; %H = 6.00; %N = 3.47. Found: %C = 56.54; %H = 5.97; %N = 3.45.

4.3.21. 2-[4-Trifluoromethyl-phenyl]-dibenzyl-methyl]-malonic acid diethyl ester (31)

White crystals; Yield: 96%; *R*_f = 0.67 (ether/hexane: 1/1); mp: 104 °C; IR (KBr, ν cm⁻¹): 2841–2902 (CH), 1731 (2C=O), 1585–1618 (C=C), 1257–1306 (C–O), 1164; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.25–7.72 (m, 4H, arom, Ph–CF₃,

³*J* = 8.1 Hz), 7.35 (m, 10H, arom, Ph, ³*J* = 6 Hz), 4.63 (d, 1H, CF₃PhC³H, ³*J* = 12 Hz), 4.4 (d, 1H, –C²H(CO₂Et)₂, ³*J* = 12 Hz), 3.0 (d, 1H, 2CH–Ph, ³*J* = 13.50 Hz), 3.9 (d, 1H, 2CHPh, ³*J* = 13.62 Hz), 4.0 (dq, 2H_{AB}, OCH₂CH₃, *J*_{AB} = 14.28 Hz, ³*J* = 7.15 Hz), 4.20–4.40 (dq, 2H_{AB}, OCH₂CH₃, *J*_{AB} = 14.28 Hz, ³*J* = 7.15 Hz), 1.28 (t, 3H, OCH₂CH₃, ³*J* = 7.11 Hz), 1.0 (t, 3H, OCH₂CH₃, ³*J* = 7.11 Hz); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.66–167.14 (2C=O), 138.53 (C_{quat}, C–CF₃–Ph), 138.09 (C_{quat}, Ph, para/CF₃), 128.17–125.01 (C_{tert}, arom), 130.22–129.43 (C_{quat}, 2C/arom, 2Ph), 61.78–61.37 (C_{sec}, 2OCH₂CH₃), 61.28 (C_{tert}, C³HPhCF₃), 55.11 (C_{tert}, C²H(CO₂Et)₂), 53.15–53.94 (C_{sec}, 2CH₂–Ph), 13.67 (C_{tert}, OCH₂CH₃), 13.91 (C_{tert}, OCH₂CH₃); SM (IE): Calc. [M]⁺ C₁₉H₂₄N₁O₅F₃: 513.54. Found [M+H]⁺ (*m/z*) = 514; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 354 (100%); Element. analysis: Calc. C₁₉H₂₄N₁O₅F₃: %C = 67.82; %H = 5.89; %N = 2.73. Found: %C = 67.79; %H = 5.87; %N = 2.72.

4.3.22. 2-[3,5-Dimethyl-pyrazol-1-yl]-4-methylphenyl-methyl]-malonic acid diethyl (32)

White crystals; Yield: 74%; *R*_f = 0.45 (ether/hexane: 1/1); mp: 88 °C; IR (KBr, ν cm⁻¹): 2872–2926 (C–H), 1752 (C=O), 1514–1594 (C=C), 1263–1305 (C–O), 1148, 1027; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.08 (d, 2H_{ortho}, ³*J* = 7.88 Hz), 7.32 (d, 2H_{meta}, ³*J* = 8.80 Hz), 5.72 (s, 1H, C⁴, Pz), 5.75 (d, 1H, Ph–C³H, ³*J* = 11.31 Hz), 4.89 (d, 1H, C²H–(CO₂Et)₂, ³*J* = 11.31 Hz), 4.14 (dq, 2H_{AB}, OCH₂CH₃, ²*J*_{AB} = 14.37 Hz, ³*J* = 7.2 Hz), 3.97 (dq, 2H_{AB}, OCH₂CH₃, ²*J*_{AB} = 14.37 Hz, ³*J* = 7.2 Hz), 2.24 (s, 3H, CH₃, Pz), 2.19 (s, 3H, CH₃, Pz), 1.13 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 0.98 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 2.29 (s, 3H, CH₃Ph); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 166.94 (2C=O), 137.9 (C_{quat}, Pz), 144 (C_{quat}, Pz), 132 (C_{quat}, CCH₃, Ph), 130.05 (C_{quat}, para-CH₃–Ph), 129.0 (C_{tert}, 2C_{meta}, Ph), 127.77 (C_{tert}, 2C_{ortho}, Ph), 105.20 (C_{tert}, C⁴H, Pz), 61.55 (C_{sec}, 2OCH₂CH₃), 60.05 (C_{tert}, C³H–Ph), 57.55 (C_{tert}, C²H–(CO₂Et)₂), 13.8–13.70 (2C_{sec}, 2OCH₂CH₃), 21.09 (C_{tert}, CH₃–Ph), 10.97–12.20 (C_{tert}, 2CH₃, Pz); SM (IE): Calc. [M]⁺ C₂₀H₂₆N₂O₄ = 358.43. Found [M+H]⁺ (*m/z*) = 359; [M–CH(CO₂Et)₂]⁺ (*m/z*) = 199 (100%); Element. analysis: Calc. C₂₀H₂₆N₂O₄: %C = 67.02; %H = 7.31; %N = 7.82. Found: %C = 66.97; %H = 7.32; %N = 7.82.

4.3.23. 2-[4-Methyl-phenyl]-piperidin-methyl]-malonic acid diethyl (33)

White crystals; Yield: 67%; *R*_f = 0.67 (ether/hexane: 1/1); mp: 91 °C; IR (KBr, ν cm⁻¹): 2873–2935 (CH), 1734 (C=O), 1493–1592 (C=C), 1289–1301 (C–O), 1180, 1013; ¹H NMR (300 MHz, CDCl₃) δ ppm: 1.32 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 1.29 (t, 3H, OCH₂CH₃, ³*J* = 7.2 Hz), 1.26 (m, 2H, C³H₂, pip), 1.49 (m, 4H, 2C²H₂, pip), 2.18 (s, 2H, C¹H₂, pip), 2.5 (s, 2H, C¹H₂, pip), 4.1 (dq, 2H_{AB}, OCH₂CH₃, ²*J*_{AB} = 9.74 Hz, ³*J* = 7.08 Hz), 4.30 (dq, 2H, OCH₂CH₃, ²*J*_{AB} = 9.74 Hz, ³*J* = 7.08 Hz), 4.22 (d, 1H, C²H(CO₂Et)₂, ³*J* = 12.13 Hz), 4.35 (d, 1H, Ph–C³H, ³*J* = 12.13 Hz), 7.03 (d, 2H_{ortho}, ³*J* = 8.82 Hz), 7.06 (d, 2H_{meta}, ³*J* = 8.82 Hz), 2.25 (s, 3H, CH₃–Ph); ¹³C NMR (300 MHz, CDCl₃) δ ppm: 167.20–168.08 (2C=O), 130.91 (C_{quat}, Ph), 137.05 (C_{quat}, CCH₃, Ph), 128.58 (2C_{tert}, meta, Ph), 58.50 (C_{tert}, ortho, Ph), 55.07 (C_{tert}, PhC²H(CO₂Et)₂), 68.81 (C_{tert}, PhC³H), 61.23–61.09 (2C, 2OCH₂CH₃), 50.53 (C, 2C¹H₂, pip), 26.46 (2C,

$2C^2H_2$, pip), 24.27 (C, C^3H_2 , pip), 14.28–13.77 (2C, $2OCH_2CH_3$); SM (IE): Calc. $[M]^+$ $C_{20}H_{29}N_1O_4$: 347.44. Found: $[M+H]^+$ (m/z) = 348; $[M-CH(CO_2Et)_2]^+$ (m/z) = 188 (100%); Element. analysis: Calc. $C_{20}H_{29}N_1O_4$: %C = 69.14; %H = 8.41; %N = 4.03. Found: %C = 69.05; %H = 8.39; %N = 4.01.

4.3.24. 2-[(3,5-Dimethyl-pyrazol-1-yl)-4-methoxyphenyl-methyl]-malonic acid diethyl (34)

White crystals; Yield: 85%; R_f = 0.63 (ether/hexane: 1/1); mp: 89 °C; IR (KBr, ν cm^{-1}): 2834–2987 (C–H), 1732 (C=O), 1534–15345 (C=C), 1223–1317 (C–O), 1148, 1027; 1H NMR (300 MHz, $CDCl_3$) δ ppm: 7.12 (d, $2H_{ortho}$, 3J = 7.88 Hz), 7.26 (d, $2H_{meta}$, 3J = 8.76 Hz), 5.67 (s, 1H, C^4 , Pz), 5.78 (d, 1H, Ph– C^3H , 3J = 11.32 Hz), 4.82 (d, 1H, $C^2H-(CO_2Et)_2$, 3J = 11.32 Hz), 4.18 (dq, $2H_{AB}$, OCH_2CH_3 , $^2J_{AB}$ = 14.29 Hz, 3J = 7.1 Hz), 3.98 (dq, $2H_{AB}$, OCH_2CH_3 , $^2J_{AB}$ = 14.32 Hz, 3J = 7.1 Hz), 2.24 (s, 3H, CH_3 , Pz), 2.19 (s, 3H, CH_3 , Pz), 1.12 (t, 3H, OCH_2CH_3 , 3J = 7.1 Hz), 1.03 (t, 3H, OCH_2CH_3 , 3J = 7.1 Hz), 2.22 (s, 3H, CH_3Ph); ^{13}C NMR (300 MHz, $CDCl_3$) δ ppm: 166.65 (2C=O), 137.9 (C_{quat} , Pz), 144 (C_{quat} , Pz), 136 (C_{quat} , $COCH_3$, Ph), 130.05 (C_{quat} , $pOCH_3-Ph$), 129.12 (C_{tert} , $2C_{meta}$, Ph), 127.73 (C_{tert} , $2C_{ortho}$, Ph), 105.20 (C_{tert} , C^4H , Pz), 61.55 (C_{sec} , $2OCH_2CH_3$), 60.02 (C_{tert} , C^3H-Ph), 57.48 (C_{tert} , $C^2H-(CO_2Et)_2$), 13.8–13.70 (2 C_{sec} , $2OCH_2CH_3$), 21.09 (C_{tert} , CH_3-Ph), 11.23–12.13 (C_{tert} , $2CH_3$, Pz).

4.3.25. 2-[(3,5-Dimethyl-pyrazol-1-yl)-4-methoxyphenyl-methyl]-malonic acid diethyl (35)

White crystals; Yield: 81%; R_f = 0.65 (ether/hexane: 1/1); mp: 92 °C; IR (KBr, ν cm^{-1}): 2823–2898 (C–H), 1752 (C=O), 1534–1554 (C=C), 1254–1319 (C–O), 1148, 1027; 1H NMR (300 MHz, $CDCl_3$) δ ppm: 7.17 (d, $2H_{ortho}$, 3J = 7.67 Hz), 7.28 (d, $2H_{meta}$, 3J = 8.67 Hz), 5.68 (s, 1H, C^4 , Pz), 5.74 (d, 1H, Ph– C^3H , 3J = 11.3 Hz), 4.83 (d, 1H, $C^2H-(CO_2Et)_2$, 3J = 11.3 Hz), 4.12 (dq, $2H_{AB}$, OCH_2CH_3 , $^2J_{AB}$ = 14.28 Hz, 3J = 7.2 Hz), 3.97 (dq, $2H_{AB}$, OCH_2CH_3 , $^2J_{AB}$ = 14.28 Hz, 3J = 7.2 Hz), 2.24 (s, 3H, CH_3 , Pz), 2.19 (s, 3H, CH_3 , Pz), 1.13 (t, 3H, OCH_2CH_3 , 3J = 7.2 Hz), 1.00 (t, 3H, OCH_2CH_3 , 3J = 7.2 Hz), 2.29 (s, 3H, CH_3Ph); ^{13}C NMR (300 MHz, $CDCl_3$) δ ppm: 167.13 (2C=O), 137.9 (C_{quat} , Pz), 144 (C_{quat} , Pz), 130.05 (C_{quat} , para- NO_2-Ph), 129.01 (C_{tert} , $2C_{meta}$, Ph), 127.77 (C_{tert} , $2C_{ortho}$, Ph), 105.20 (C_{tert} , C^4H , Pz), 61.55 (C_{sec} , $2OCH_2CH_3$), 60.05 (C_{tert} , C^3H-Ph), 57.55 (C_{tert} , $C^2H-(CO_2Et)_2$), 13.8–13.70 (2 C_{sec} , $2OCH_2CH_3$), 21.09 (C_{tert} , CH_3-Ph), 10.97–12.20 (C_{tert} , $2CH_3$, Pz).

4.3.26. Synthesis of complex $[Cu_2(CH_3COO^-)4(H_2O)_2]$ (36)

The KOH (0.058 g; 1.05 mmol) was added to a solution of 2-[(4-chlorophenyl)-3,5-dimethyl-pyrazol-1-yl-methyl]-malonic acid diethyl (25) (0.2 g; 0.52 mmol) in ethanol (15 mL) and the stirring was continued under reflux in ethanol (4 h), until the complete saponification of the starting material. After addition of $Cu(NO_3)_2 \cdot 3H_2O$, the color changed from blue to purple. The stirring was further continued for additional 6 h. The organic solvent was evaporated slowly over a period of 2 days to give a pure paramagnetic compound as purple crystals (36). Purple crystals; Yield: 55%; Decomposition > 260 °C; IR (KBr, ν cm^{-1}): 2934–2988 (CH), 1595 (C=O), 1416 (C=O), 3269–3466 (OH, H_2O), 1354, 1092, 830. The ORTEP view of (36) is given in Fig. 3.

5. Conclusion

In spite of having prolonged reaction time, this aza-Michael addition protocol led to higher yields in an aqueous medium at room temperature, and consequently, would appear to be a simple and useful synthetic protocol. Considering its high efficiency to run at gram-scale level and especially high purity of the final products, this protocol is thus of great usefulness for the synthesis of potentially new drug candidates. The X-ray crystal structures of (17) and (24) were studied first time and found in complete agreement with the proposed one than in solution.

6. Supplementary data

Supplementary crystallographic data for the reported compounds (17) and (24) are available from the CCDC, 12 Union-Road, Cambridge CB2 1EZ, UK on request, quoting the deposition number CCDC 734201 and CCDC 734199.

Acknowledgement

This work was supported by the grant sanctioned from the Project Global de Recherche de l'Université Mohammed Premier/LCM (Morocco).

References

- Amslinger, S., 2010. The tunable functionality of α,β -unsaturated carbonyl compounds enables their differential application in biological systems. *ChemMedChem* 5, 351–356.
- Bacchi, A., Biemmi, M., Carcelli, M., Carta, F., Compari, C., Fiscaro, E., Rogolino, D., Sechi, M., Sippel, M., Sottriffer, C.A., Sanchez, T.W., Neamati, N., 2008. From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by β -diketo acid metal complexes. *Journal of Medicinal Chemistry* 51, 7253–7264.
- Basu, B., Das, P., Hossain, I., 2004. Synthesis of β -amino esters via aza-Michael addition of amines to alkenes promoted on silica: a useful and recyclable surface. *Synlett*, 2630–2632.
- Dayam, R., Al-Mawsawi, L.Q., Neamati, N., 2007. Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. *Bioorganic and Medicinal Chemistry Letters* 17, 6155–6159.
- Dayam, R., Neamati, N., 2004. Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design. *Bioorganic and Medicinal Chemistry* 12, 6371–6381.
- Goldgur, Y., Craigie, R., Cohen, G.H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., Davies, D.S., 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. *Proceedings of the National Academy of Sciences of the United States of America* 96, 13040–13043.
- Gopi, H., Cocklin, S., Pirrone, V., McFadden, K., Tuzer, F., Zentner, I., Ajith, S., Baxter, S., Jawanda, N., Krebs, F.C., Chaiken, I.M., 2009. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120. *Journal of Molecular Recognition* 22, 169–174.
- Hayashi, Y., Rode, J.J., Corey, E.J., 1996. A novel chiral super-Lewis acidic catalyst for enantioselective synthesis. *Journal of American Chemical Society* 118, 5502–5503.
- Kumar, D., Patel, G., Mishra, B.G., Varma, R.S., 2008. Eco-friendly polyethylene glycol promoted Michael addition reactions of α,β -

- unsaturated carbonyl compounds. *Tetrahedron Letters* 49, 6974–6976.
- Lebon, F., Boggetto, N., Ledecq, M., Durant, F., Benatallah, Z., Siscic, S., Lapouyade, R., Kahn, O., Mouithys-Mickalad, A., Deby-Dupont, G., Reboud-Ravaux, M., 2002. Metal-organic compounds: a new approach for drug discovery. N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease.. *Biochemical Pharmacology* 63, 1863–1873.
- Meskini, I., Daoudi, M., Daran, J.-C., Hadda, T.B., Zouihri, H., 2010a. Poly[[bis(μ_3 -2-[(3,5-dimethyl-1-*H*-pyrazol-1-yl)(phenyl)methyl]propanedioato)tetrasodium(I)] 7.5-hydrate]. *Acta Crystallographica Section E* E66, m1009–m1010.
- Meskini, I., Toupet, L., Daoudi, M., Kerbal, A., Akkurt, M., Chohan, Z.H., Hadda, T.B., 2010b. Structure of 2-[(phenyl)-(3,5-dimethylpyrazol-1-yl)-methyl]-malonic acid diethyl ester. *Journal of Chemical Crystallography* 40, 812–815.
- Meskini, I., Toupet, L., Daoudi, M., Kerbal, A., Bennani, B., Dixneuf, P.H., Chohan, Z.H., Leite, A.C.L., Hadda, T.B., 2010c. *Journal of Brazilian Chemical Society* 21, 1129–1135.
- Orvig, C., Abrams, M., 1999. Medicinal inorganic chemistry: introduction. *Chemical Reviews* 99, 2201–2203.
- Ranu, B.C., Banerjee, S., 2007. Significant rate acceleration of the azo-Michael reaction in water. *Tetrahedron Letters* 48, 141–143.
- Ranu, B.C., Dey, S.S., Samanta, S., 2005. Indium(III) chloride-catalyzed Michael addition of thiols to chalcones: a remarkable solvent effect. *Arkivoc* 3, 44–50.
- Ranu, B.C., Mandal, T., 2007. Efficient synthesis of β -alkyl/arylsulfanyl carbonyl compounds by in-TMSCl-promoted cleavage of dialkyl/diaryl disulfides and subsequent Michael addition. *Synthetic Communications* 37, 1517–1523.
- Sechi, M., Bacchi, A., Carcelli, M., Compari, C., Duce, E., Fiscaro, E., Rogolino, D., Gates, P., Derudas, M., Al-Mawsawi, L.Q., Neamati, N., 2006. From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by β -diketo acid metal complexes. *Journal of Medicinal Chemistry* 49, 4248–4260.
- Sechi, M., Carta, F., Sannia, L., Dallochio, R., Dessi, A., Al-Safi, R.A., Neamati, N., 2009. Design, synthesis, molecular modeling, and anti-HIV-1 integrase activity of a series of photoactivatable diketo acid-containing inhibitors as affinity probes. *Antiviral Research* 81, 267–276.
- Sorrell, T.N., Vankai, V.A., Garrity, M.L., 1991. Synthesis and reactivity of dinuclear copper complexes having a *m*-xylyl spacer between coordination units. *Inorganic Chemistry* 30, 207–210.
- Wabnitz, T.C., Spencer, J.B., 2002. Convenient synthesis of Cbz-protected β -amino ketones by a copper-catalysed conjugate addition reaction. *Tetrahedron Letters* 43, 3891–3894.
- Walker, M.A., Johnson, T., Naidu, B.N., Banville, J., Remillard, R., Plamondon, S., Martel, A., Li, C., Torri, A., Samanta, H., Lin, Z., Dicker, I., Krystal, M., Meanwell, N.A., 2007. Benzyl amide-ketoacid inhibitors of HIV-integrase. *Bioorganic and Medicinal Chemistry Letters* 17, 4886–4890.
- Zenga, L.-F., Jianga, X.-H., Sanchezb, T., Zhanga, H.S., Dayam, R., Neamati, N., Long, Y.-Q., 2008. Novel dimeric aryldiketo containing inhibitors of HIV-1 integrase: effects of the phenyl substituent and the linker orientation. *Bioorganic and Medicinal Chemistry* 16, 7777–7787.
- Zhu, Q., Jiang, H., Li, J., Zhang, M., Wang, M., Qic, C., 2009. Practical synthesis and mechanistic study of polysubstituted tetrahydropyrimidines with use of domino multicomponent reactions. *Tetrahedron* 65, 4604–4613.